Circulating Tumor Cells Patent Landscape and Forecast 2024-2032 - The U.S. Leads with Over 4,000 Patent Filings, Driven by Robust R&D Infrastructure and Substantial Investments in Cancer Diagnostics [Yahoo! Finance]
LowReport
Circulating Tumor Cells Patent Landscape and Forecast 2024-2032 - The U.S. Leads with Over 4,000 Patent Filings, Driven by Robust R&D Infrastructure and Substantial Investments in Cancer Diagnostics [Yahoo! Finance]
IDEX Co. (NYSE: IEX) had its price target raised by analysts at Royal Bank of Canada from $236.00 to $248.00. They now have an "outperform" rating on the stock.
LowReport
IDEX Co. (NYSE: IEX) had its price target raised by analysts at Royal Bank of Canada from $236.00 to $248.00. They now have an "outperform" rating on the stock.
IDEX Co. (NYSE: IEX) had its price target lowered by analysts at Robert W. Baird from $245.00 to $241.00. They now have an "outperform" rating on the stock.
LowReport
IDEX Co. (NYSE: IEX) had its price target lowered by analysts at Robert W. Baird from $245.00 to $241.00. They now have an "outperform" rating on the stock.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: